P J Morley - JoVE Visualize

Showing results (1-10 of 9) with videos related to

Pageof 1

Sort By:

Archives of Biochemistry and Biophysics|August 1, 1984

A carbon-13 NMR comparative study of metal ion substitutions in human carbonic anhydrase I carboxymethylated at active-site histidine-200R G Khalifah, P J Morley

Journal of Medical Virology|September 26, 2000

Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challengeT A Gill, P J Morley, C Sweet

Plant Biology (Stuttgart, Germany)|January 28, 2022

Satellite data track spatial and temporal declines in European beech forest canopy characteristics associated with intense drought events in the Rhön Biosphere Reserve, central GermanyE West, P J Morley, A S Jump, et al.

Antimicrobial Agents and Chemotherapy|October 30, 1999

Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tractR J Fenton, P J Morley, I J Owens, et al.

Virology|July 10, 1998

The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2enT J Blick, A Sahasrabudhe, M McDonald, et al.

Journal of Clinical Immunology|July 9, 2013

Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1M C Holland, J U Wurthner, P J Morley, et al.

Clinical and Experimental Immunology|July 17, 2015

Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1J C Cordy, P J Morley, T J Wright, et al.

Antimicrobial Agents and Chemotherapy|December 22, 1999

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studiesJ M Barnett, A Cadman, D Gor, et al.

Journal of Medicinal Chemistry|April 4, 1998

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamidesP W Smith, S L Sollis, P D Howes, et al.

Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:

Pageof 1

Archives of Biochemistry and Biophysics|August 1, 1984

A carbon-13 NMR comparative study of metal ion substitutions in human carbonic anhydrase I carboxymethylated at active-site histidine-200R G Khalifah, P J Morley

Journal of Medical Virology|September 26, 2000

Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challengeT A Gill, P J Morley, C Sweet

Plant Biology (Stuttgart, Germany)|January 28, 2022

Satellite data track spatial and temporal declines in European beech forest canopy characteristics associated with intense drought events in the Rhön Biosphere Reserve, central GermanyE West, P J Morley, A S Jump, et al.

Antimicrobial Agents and Chemotherapy|October 30, 1999

Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tractR J Fenton, P J Morley, I J Owens, et al.

Virology|July 10, 1998

The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2enT J Blick, A Sahasrabudhe, M McDonald, et al.

Journal of Clinical Immunology|July 9, 2013

Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1M C Holland, J U Wurthner, P J Morley, et al.

Clinical and Experimental Immunology|July 17, 2015

Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1J C Cordy, P J Morley, T J Wright, et al.

Antimicrobial Agents and Chemotherapy|December 22, 1999

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studiesJ M Barnett, A Cadman, D Gor, et al.

Journal of Medicinal Chemistry|April 4, 1998

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamidesP W Smith, S L Sollis, P D Howes, et al.

Pageof 1